InnovaDerma PLC Stocks

£ 0Last Updated 23.03.2026

Issuer Rating

Performance

Average

Risk

Negligible

Recommendation

Sell

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
£ 0
Key Takeaways

Risk factor

Limited default risk

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

InnovaDerma PLC, through its subsidiaries, engages in the research, manufacture, and marketing of clinically proven products in life sciences, beauty, and personal care products in the United Kingdom, the United States, Australasia, and the Asia Pacific region. The company offers a range of men's skincare products, including hand and body washes, hand creams, face washes, and face moisturizers under the Charles + Lee brand name; and hair removal wax and jelly, and shave and shower sorbet under the Nuthing brand. It also provides tanning mousses, tanning gels, tanning oils, primers, moisturizers, and applicators under the Skinny Tan brand name; Prolong, a Class II medical device for the treatment of premature ejaculation; haircare products comprising shampoos, conditioners, and spray treatment for men and women to aid hair regrowth and hair thickening under the Roots brand name; and hair growth products under the GrowLase brand. The company sells its products through online and DTC channels. InnovaDerma PLC was incorporated in 2014 and is headquartered in London, the United Kingdom.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks